Fibrobiologics Inc's stock has surged by 12.20% in pre-market trading, crossing above its 5-day SMA. This movement occurs amid a generally stable market, with the Nasdaq-100 and S&P 500 both showing negligible changes.
The stock's rise can be attributed to sector rotation, as investors are increasingly focusing on biotech companies, which have shown resilience in the current market environment. This shift in investor sentiment is likely driven by ongoing developments in the biotech sector, which are attracting attention despite the overall market's flat performance.
As the market continues to evolve, Fibrobiologics Inc's strong performance may indicate a growing interest in its pipeline and potential future developments, positioning the company favorably within the biotech landscape.
Wall Street analysts forecast FBLG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBLG is 3.25 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FBLG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBLG is 3.25 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.341
Low
1.50
Averages
3.25
High
5.00
Current: 0.341
Low
1.50
Averages
3.25
High
5.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$10 -> $5
2025-11-05
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $5
AI Analysis
2025-11-05
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on FibroBiologics to $5 from $10 and keeps a Buy rating on the shares. The firm adjusted the company's model to reflect an updated share count and tempered factor of patients receiving FibroBiologics' novel diabetic foot ulcer treatment pending further clinical validation.
H.C. Wainwright
Matthew Caufield
Buy
downgrade
$12 -> $10
2025-08-05
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$12 -> $10
2025-08-05
downgrade
Buy
Reason
H.C. Wainwright analyst Matthew Caufield lowered the firm's price target on FibroBiologics to $10 from $12 and keeps a Buy rating on the shares. The firm says the company's progress continues across therapeutic fibroblast development.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FBLG
Unlock Now
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$16
2025-04-09
Reason
D. Boral Capital
Jason Kolbert
Price Target
$16
2025-04-09
Maintains
Strong Buy
Reason
FibroBiologics announced a significant advancement in neurodegenerative disease research. Leveraging the Cuprizone animal model, FibroBiologics has demonstrated that intravenous fibroblasts can facilitate remyelination. FibroBiologics' Cuprizone animal model study demonstrated a statistically significant increase in myelin expression within seven weeks after both single and multiple dose fibroblast treatments. This confirms FibroBiologics' previous report of remyelination with the Experimental Autoimmune Encephalomyelitis animal model. "This confirmation by our talented team of researchers demonstrates that fibroblasts can support the regeneration of myelin sheath, marking a potentially significant step in the utilization of a cell-based therapeutic in regenerative medicine," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$16
2025-04-01
Reason
D. Boral Capital
Jason Kolbert
Price Target
$16
2025-04-01
Maintains
Strong Buy
Reason
About FBLG
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
